| Literature DB >> 21073696 |
Sabah Hedhili1, Marie-Véronique De Mattei, Yoan Coudert, Isabelle Bourrié, Yves Bigot, Pascal Gantet.
Abstract
BACKGROUND: CrMYC2 is an early jasmonate-responsive bHLH transcription factor involved in the regulation of the expression of the genes of the terpenic indole alkaloid biosynthesis pathway in Catharanthus roseus. In this paper, we identified the amino acid domains necessary for the nuclear targeting of CrMYC2.Entities:
Year: 2010 PMID: 21073696 PMCID: PMC2994886 DOI: 10.1186/1756-0500-3-301
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Oligonucleotides used for the amplification of full-length or deletion mutants of Crmyc2 or for the reconstitution of sequences encoding the putative NLSs of the CrMYC2 protein
| Fusion protein | Nucleotide sequences of primers used to amplify the | |
|---|---|---|
| CrMYC2 | forward | 5'-CCG |
| reverse | 5'-CCG | |
| F1 | forward | 5'-CCG |
| reverse | 5'-CCG | |
| F2 | forward | 5'-CCG |
| reverse | 5'-CCG | |
| F3 | forward | 5'-CCG |
| reverse | 5'-CCG | |
| F4 | forward | 5'-CCG |
| reverse | 5'-CCG | |
| F5 | forward | 5'-CCG |
| reverse | 5'-CCG | |
| F6 | forward | 5'-CCG |
| reverse | 5'-CCG | |
| F7 | forward | 5'-CCG |
| reverse | 5'-CCG | |
| F8 | forward | 5'-CCG |
| reverse | 5'-CCG | |
| NLS1 | forward | 5'- |
| reverse | 5'- | |
| NLS2 | forward | 5'- |
| reverse | 5'- | |
| NLS3 | forward | 5'- |
| reverse | 5'- | |
| NLS4 | forward | 5' |
| reverse | 5'- | |
Underlined sequences represent the positions of the restriction sites used for cloning the PCR products into the GFP-pEMBL18 or pTH2BN vectors.
Figure 1Schematic representation of the full-length CrMYC2 protein showing the positions of the potential nuclear localization signal sequences (NLS 1, 2, 3, and 4) and of the regions of CrMYC2 used to make the GFP fusions. NLS: nuclear localization signal, CrMYC2: full-length CrMYC2 sequence, F1 to F8: partial CrMYC2 sequences used for fusion to GFP. Grey box: bHLH domain. Single oval shape: monopartite NLS. Double oval shape: bipartite NLS.
Figure 2Alignment of amino acid sequences of CrMYC2, AtMYC2/RAP1/AtbHLH006/At1g32640.1, At4g17880.1, At5g46760.1, At5g46830.1 and Os10g42430.1. Bold letters correspond to conserved amino acids residues within a putative NLS. Basic amino acids are boxed in grey. Asterisks under sequences correspond to positions where the amino acid is the same for all sequences. Boxed or underlined sequences indicate the three regions involved in CrMYC2 nuclear targeting.
Figure 3Subcellular localization in epidermal onion cells of fusions of GFP with full-length CrMYC2, with different putative nuclear localization signals and with deletion mutants of CrMYC2. The green fluorescence of the GFP protein was visualized by epifluorescence microscopy. A: control with GFP alone. B: control with GFP fused to the NLS of the SV40 large T antigen. C: control with GFP fused to an endoplasmic reticulum retention signal. D: right, GFP fused to full-length CrMYC2, left: corresponding DAPI staining,. E-H: GFP fused with different putative NLS sequences from CrMYC2, 1, 2, 3 and 4, respectively; I-P: GFP fused with different deletion mutants of CrMYC2 (F1 to F8).